Browse All

Current Filters

CLEAR FILTER x

TITLE

Real-world Switching Rates of Atogepant Are Lower than CGRP Monoclonal Antibodies (mAbs) in Patients with Migraine Using Claims Database

Treatment with Zavegepant Offers Improvements in Pain Severity Over 48-hours When Compared with Placebo—Post Hoc Results from a Randomized Placebo-controlled Trial (BHV3500-301)